# Kronos Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kronos-bio

- Industry: Biotechnology
- Headquarters: San Mateo, US
- Total disclosed funding: $123M
- Latest round: Series A (Jul 1, 2019)
- Investors on record: 8

## About

Founded in 2017 and headquartered in San Mateo, US, Kronos Bio, Inc. specializes in targeting gene regulation to create cancer treatments. The company has engaged in 4 deals, with its most recent deal being an IPO on October 8, 2020, raising USD 250.00 mn by selling 13.157 million shares at USD 19 per share on the Nasdaq. The CEO is Norbert Bischofberger.

Kronos Bio, Inc. develops a range of cancer therapies aimed at inhibiting specific cellular pathways involved in tumor growth. The company's core offerings focus on innovative drug candidates that target gene transcription and regulatory mechanisms, which are critical in cancer biology. Their products are marketed worldwide, catering to oncologists, hospitals, and research institutions that seek effective cancer treatment options.

## Funding rounds

- Series A, Jul 1, 2019, $105M — Polaris Partners, Invus [DUP], Nextech, GV, Omega Funds, Perceptive Advisors, Vida Ventures
- Seed, May 23, 2018, $18M — Omega Funds, Vida Ventures, Bellco Capital

## Investors

- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Seed, Series A
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Seed, Series A
- Bellco Capital (https://capitalatlas.ai/funds/bellco-capital) — Seed
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Invus [DUP] — Series A
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A